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Inhibition of stromal cell-derived factor-1 further
impairs diabetic wound healing
Dustin M. Bermudez, MD,a,b Junwang Xu, MD,c Benjamin J. Herdrich, MD,a Antoneta Radu, BS,b
Marc E. Mitchell, MD,c and Kenneth W. Liechty, MD,c Philadelphia, Pa; and Jackson, Miss
Objective: Impaired diabetic wound healing is associated with abnormal stromal cell-derived factor (SDF)-1 production,
decreased angiogenesis, and chronic inflammation. Lentiviral-mediated overexpression of SDF-1 can correct the
impairments in angiogenesis and healing in diabetic wounds. We hypothesized that SDF-1 is a critical component of the
normal wound-healing response and that inhibition of SDF-1 would further delay the wound-healing process.
Methods: dB/Db diabetic mice and Db/ nondiabetic mice were wounded with an 8-mm punch biopsy and the wounds
treated with a lentiviral vector containing either the green fluorescent protein (GFP) or SDF-1 inhibitor transgene. The
inhibitor transgene is a mutant form of SDF-1 that binds, but does not activate, the CXCR4 receptor. Computerized
planimetry was used to measure wound size daily. Wounds were analyzed at 3 and 7 days by histology and for production
of inflammatory markers using real-time polymerase chain reaction. The effect of the SDF-1 inhibitor on cellular
migration was also assessed.
Results: Inhibition of SDF-1 resulted in a significant decrease in the rate of diabetic wound healing, (3.8 vs 6.5 cm2/day
in GFP-treated wounds; P  .04), and also impaired the early phase of nondiabetic wound healing. SDF-1 inhibition
resulted in fewer small-caliber vessels, less granulation tissue formation, and increased proinflammatory gene expression
of interleukin-6 and macrophage inflammatory protein-2 in the diabetic wounds.
Conclusions: The relative level of SDF-1 in the wound plays a key role in the wound-healing response. Alterations in the
wound level of SDF-1, as seen in diabetes or by SDF-1 inhibition, impair healing by decreasing cellular migration and
angiogenesis, leading to increased production of inflammatory cytokines and inflammation. Inhibition of SDF-1 further
impairs diabetic wound healing. (J Vasc Surg 2011;53:774-84.)
Clinical Relevance: Diabetes results in a significant impairment in wound healing, leading to significant morbidity and
health care expenditures. The pathophysiology that underlies this process is multifactorial, including abnormal growth
factor production, cellular migration, and cellular function. Stromal cell-derived factor (SDF)-1 is a key chemokine
involved in the wound-healing process and is involved in cellular recruitment and angiogenesis. SDF-1 is decreased in
diabetic individuals. This study showed that inhibition of SDF-1 results in an even more dramatic delay in the diabetic
wound-healing process and even results in a delay in the early phases of wound healing in normal mice, further supporting
its role in wound healing. Inhibition of this chemokine promotes greater inflammatory cytokine production, inflamma-
tory cell migration, and less vasculogenesis after dermal wounding. This study identifies SDF-1 as an essential
component of normal wound healing and provides a potential therapeutic target to improve the diabetic wound-healing
impairment.
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cDiabetes has reached pandemic proportions in the
United States and across the globe. Expenditures on dia-
betes care in the United States was$174 billion in 2007.1
An ulcer of the lower extremity precedes 84% of all diabetic
lower extremity amputations and is the primary cause for
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774ospitalization among diabetic individuals.2 Despite the
ncreasing prevalence of diabetes, current therapies have
ot decreased the incidence of amputation or lower ex-
remity ulcer formation.
Hyperbaric oxygen, recombinant platelet-derived growth
actor (PDGF), and biosynthetic grafts all have been exten-
ively studied as alternative methods to promote the
ound-healing process.3-10 Although promising, their use
as not been widespread. Hyperbaric oxygen has been
emonstrated to increase numbers of endothelial progeni-
or cells (EPCs) in animal studies as well as in vitro studies,
ut not in humans.11 Recombinant PDGF application to
iabetic wounds demonstrates some reproducible improve-
ent of the wound-healing process.7 Apligraf (Novartis,
ast Hanover, NJ) or Dermagraft (Dermagraft, Westport,
onn) are both biosynthetic grafts used to promote wound
losure in diabetic patients.9,10 Although there is evidence
o support the benefit of these therapies when used clini-
ally, widespread use is tempered by their prohibitive
osts.12
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Volume 53, Number 3 Bermudez et al 775The molecular physiology that underlies the diabetic
wound-healing defect remains unclear. The wounds of
diabetic individuals present with fewer EPCs, greater in-
flammation, and fewer growth factors.13-19 Specifically,
deficiencies in growth factors such as PDGF, keratinocyte
growth factor, transforming growth factor- (TGF-), he-
patocyte growth factor, and vascular endothelial growth
factor, have all been implicated in the delayed healing rates
observed in chronic diabetic wounds.13-19 Chronic diabetic
wounds have been shown to have deficiencies in the cellular
response to growth factors, including decreased cellular re-
cruitment and migration, decreased angiogenesis and granu-
lation tissue production, impaired re-epithelialization, de-
creased extracellular matrix production, and impaired wound
contraction.13-19
Stromal-derived factor-1 (SDF-1), a CXC chemo-
kine implicated in the wound-healing process16-19 in the
Leprdb mouse model of type II diabetes can correct this
wound-healing defect when overexpressed.20 Greater
granulation tissue, smaller epithelial gap, and smaller
wound size were all found on histologic analysis. To exam-
ine the role of SDF-1 in impaired and nonimpaired
wound healing, we injected a lentiviral vector that expresses
a mutant form of SDF-1 that binds, but does not activate,
CXC chemokine receptor type 4 (CXCR4) and measured
its effect on granulation tissue formation, angiogenesis,
inflammation, cell migration, and wound healing.
METHODS
Lentiviral vector construction and fibroblast tran-
sduction. The SDF mutant we generated binds the
CXCR4 receptor but does not activate it, based on studies
by Choi et al,21 using site-directed mutagenesis to evaluate
the effect of specific mutations in the SDF-1 gene on
CXCR4-mediated signal transduction. Replacement of the
C-terminal proline amino acid with glycine generates a
mutated form of SDF-1 that binds to the CXCR4 recep-
tor but does not activate it.
A complementary DNA library was prepared from
mouse tissues using Trizol and Superscript (Invitrogen,
Carlsbad, Calif) according to the manufacturer’s instruc-
tions. Sequence analysis was used to confirm the murine
SDF-1 cDNA as well as the SDF-1 inhibitor.
The CS-CG HIV-1 transfer plasmid, modified as previ-
ously described,22,23 was used to generate a self-inactivating
lentiviral vector. This lentiviral vector allows expression of
the green fluorescent protein (GFP) reporter gene (Clon-
tech Laboratories, Mountain View, Calif) or the mutant
SDF-1 construct with the GFP reporter gene as a single
transcript under the control of a cytomegalovirus pro-
moter. Vesicular stomatitis virus-G protein pseudotyped
viral particles were generated by transfection into a 293T
cell line and titered, as previously described.24
To test the ability of our viral construct to efficiently
infect cells and produce transgene protein, we incubated
passage five dermal fibroblasts with our lentiviral construct
at a multiplicity of infection of 100 for 24 hours. Trans-
duced fibroblasts were then plated in 12-well tissue culture slates at a seeding density of 5  105 cells/well. Tissue
ulture supernatants were aspirated from the plates 24
ours after transfection then frozen at 80°C. SDF-1
rotein content was determined from thawed supernatants
sing a Quantikine enzyme-linked immunosorbent assay
it for murine CXCL12/SDF-1 (R&D Systems, Minne-
polis, Minn) according to the manufacturer’s instructions.
ll transduced cells produced 100 ng/mL of SDF-1
nhibitor.
Experimental animals and surgical procedure. All
xperimental protocols used in this study were approved by
he Institutional Animal Care and Use Committee at the
hildren’s Hospital of Philadelphia. Genetically diabetic,
0- to 12-week-old, female C57BKS.Cg-m/Leprdb mice
nd age-matched nondiabetic heterozygous mice (Jackson
aboratory, Bar Harbor, Me) were used in this study. At
he time of wounding, dB/Db mice weighed 45 g with
lood glucose levels 400 mg/dL and Db/ heterozy-
ote mice weighed 25 g with blood glucose levels 250
g/dL. Animals were given standard rodent chow and
ater ad libitum.
Each mouse was shaved and depilated before wound-
ng. The dorsal skin was swabbedwith alcohol and Betadine
Purdue Pharma, Stamford, Conn). Each mouse under-
ent a single dorsal full-thickness wound (including pan-
iculus carnosum) with an 8-mm punch biopsy (Miltex
nc, York, Pa). After wounding, a Hamilton syringe was
sed to deliver 50 L of the lentiviral SDF-1 inhibitor
ector or a lentiviral GFP vector as a control. Ten microli-
ers were injected intradermally at the 12, 3, 6, and 9
’clock positions and at the wound base. Approximately
 108 plaque forming units (PFUs) of the lentiviral
onstructs were used on each mouse. Next, a sterile Tega-
erm (3M, St. Paul, Minn) was placed over the wound and
eft in place for 48 hours, after which it was removed.
Planimetry and wound size calculation. Photo-
raphs were obtained with a Nikon camera using a ruler for
ach image. ImageJ software (National Institutes of
ealth, Bethesda, Md; http://rsbweb.nih.gov/ij/) was
sed to calculate the wound area of each mouse daily. The
ame observer measured the size of each wound. Wound
rea was plotted daily as a function of time.
Immunohistochemistry and histologic analysis.
ounds were harvested at days 3 and 7 and immediately
xed in 10% neutral buffered formalin (Sigma, St. Louis,
o). The tissue was processed using a histoprocessor
Leica TP1050, GMI Inc, Ramsey,Minn). Paraffin sections
ere cut 4 m thick, mounted on slides, and incubated
Fisher Scientific, Pittsburgh, Pa) overnight. Slides were
eparaffinized and washed in ethanol. Endogenous perox-
dase was quenched with 0.3% hydrogen peroxide for 30
inutes at room temperature. Slides were pretreated with
roteinase K (Dako, Carpinteria, Calif) for 10 minutes and
insed with distilled water. Primary murine -smooth mus-
le actin (-SMA; 1:200), CD31 (1:50), and CD45 (1:50)
ntibodies (BD Biosciences, San Jose, Calif) were applied.
hey were developed with a Vectastain Elite ABC kit with
econdary antibody (Vector Laboratories, Burlingame,
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March 2011776 Bermudez et alCalif). A blinded observer analyzed granulation tissue area,
-SMA vessel density, and numbers of CD31 and
CD45 cells per high-power field (HPF). Three HPFs per
slide were examined.
Real-time quantitative polymerase chain reaction.
Wounds were harvested at days 3 and 7 after wounding and
frozen in liquid nitrogen. Samples were homogenized in
TRIzol (Invitrogen), and total RNA was extracted and puri-
fied following themanufacturer’s instructions. RNAwas con-
verted into complementary DNA using the SuperScript
First-Strand Synthesis System (Invitrogen). Real-time poly-
merase chain reaction (PCR) was performed with the ABI
7900 real-time PCR thermal cycler (Applied Biosystems,
Foster City, Calif) to amplify samples in triplicate. All
samples were amplified using TaqMan prepared primer
assays. The average of the triplicate gene product for each
gene was compared with 18S ribosomal RNA expression to
generate a relative fold-expression. Results were reported as
means	 SEM. A total of 19 mice (with 4 groups of 5 mice
each) were sacrificed to perform PCR analysis, with a total
of 57 PCR reactions performed.
Cellular migration. A standard 24-well colorimetric
assay was used to assess cellular migration. Boyden cham-
bers (Chemicon, Santa Cruz, Calif) equipped with 8-m
pore diameter polycarbonate filters were used. Cells were
suspended in migration medium (1 g/mL heparin/0.1%
bovine serum albumin in Dulbecco’s Modified Eagle Me-
dium) and 2  105 cells were loaded into the upper
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Fig 1. A,Diabetic wounds are shown at day 7 in the gre
factor inhibitor (SDFi)-treated mice. B,Mean wound are
vector at each day after wounding (each data point, n 

experimental groups at day 7.D,Daily mean wound area
The days after wounding at which there was a significant
the asterisk above the graph.chamber. The lower chambers were plated 24 hours before .he migration assay with one of five conditions: (1) fibro-
lasts alone, (2) fibroblasts transfected with lenti-SDF-1,
3) fibroblasts transfected with lenti-SDF-1 and fibro-
lasts transfected with the lenti-SDF-1 inhibitor at a ratio
f 1:1 and (4) at a ratio of 1:2, and (5) no cells. The cells
lated before migration were done so with 2  105 cells.
his lower chamber was washed with phosphate-buffered
aline and filled with migration medium. After 16 hours,
ells in themigrationmediumwere removed and quantified
nder a light microscope (original magnification20) after
taining with 0.5% crystal violet. All migration experiments
ere done in triplicate.
Statistical methods. Data are presented as mean 	
EM to two significant figures. Statistical analysis was per-
ormed with one-way analysis of variance using SPSS 16.0
oftware (SPSS Inc, Chicago, Ill). Values were transformed
ln) when required to achieve normality of sampling. When
ignificant differences (P  .05) were found, a least signif-
cant difference post hoc test, Mann-Whitney U, was used
o identify differences between individual means.
ESULTS
Wound healing. Treatment of diabetic wounds with
he lenti-SDF-1 inhibitor resulted in a significant and
urther impairment in wound healing. Diabetic wounds
reated with lentiviral-SDF inhibitor were significantly
arger at day 7 (0.25	 0.006 cm2) compared with diabetic
ounds treated with lentiviral GFP (0.16	 0.05 cm2; P
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Volume 53, Number 3 Bermudez et al 777lenti-SDF-1 inhibitor also resulted in a dramatic delay in
the mean number of days to wound closure when com-
pared with the lenti-GFP group (25 	 2.5 vs 15.1 	 1.3
days to closure; P  .0021). In addition, treatment of
diabetic wounds with the lenti-SDF-1 inhibitor resulted
in a dramatic decrease in the rate of wound closure of 3.8	
0.94 mm2/d in the lenti-SDF-1 inhibitor group (n 
 5)
vs 6.5 	 2.2 mm2/d in the lenti-GFP group (n 
 5; P 

.04; Fig 1, B).
Treatment of nondiabetic wounds with the lenti-
SDF-1 inhibitor demonstrated a significant impairment in
the initial phase of wound healing, with increased wound
area in days 1 to 5 vs the group treated with lenti-GFP (P
.03; Fig 1, C). However, the mean wound area after 5 days
and the overall rate of wound closure for the nondiabetic
wounds treated with SDF-1 inhibitor were not signifi-
cantly different from GFP-treated wounds. The mean
wound area over time is shown in Fig 1, D.
Granulation tissue. The effect of the lenti-SDF-1
inhibitor on granulation tissue was assessed at 7 days using
trichrome staining and measurement of the granulation
tissue volume. Representative sections of granulation tissue
from diabetic mice treated with lenti-GFP and those
treated with lenti-SDF inhibitor are displayed in Fig 2, A
and B, respectively. Treatment with the lenti-SDF-1 in-
hibitor resulted in a significant decrease in the granulation
tissue volume (1.8 	 0.4/mm2; P 
 .031; Fig 2, E)
compared with the lenti-GFP treated diabetic wounds
(1.1 	 0.46/mm2). Diabetic wounds also demonstrated
significantly less granulation tissue than nondiabetic
wounds (Fig 2, C and D).
Representative sections of granulation tissue from non-
diabetic mice treated with lenti-GFP are shown in Fig 2, C,
and from those treated with lenti-SDF-1 inhibitor in Fig
2, D. The mean granulation tissue volume was not signifi-
cantly different (2.4 	 0.32 vs 2.5 	 0.94/mm2; P 
 .31;
Fig 2, E).
Angiogenesis. The effect of the lenti-SDF-1 inhibi-
tor on angiogenesis was assessed using immunohistochem-
istry for CD31, an endothelial marker. Representative im-
ages of immunoperoxidase staining for CD31 at 7 days in
diabetic wounds treated with lenti-GFP or lenti-SDF-1
inhibitor are demonstrated in Fig 3, A and B. Treatment
with the SDF-1 inhibitor resulted in a significant de-
crease in the number of CD31 cells/HPF (5.1 	 1.83
[n 
 5]; P 
 .005; Fig 3, E) vs lenti-GFP–treated
wounds (7.1 	 1.75).
Representative images of CD31 staining in nondiabetic
wounds treated with lenti-GFP and lenti-SDF-1 inhibitor
are displayed in Fig 3, C and D, respectively. Treatment of
nondiabetic wounds with the lenti-SDF-1 inhibitor re-
sulted in a significant decrease in the number of CD31
cells/HPF (10.1 	 4.45 [n 
 10]; P 
 .04; Fig 3, E)
compared with nondiabetic wounds treated with lenti-GFP
(13.3 	 3.75). In addition, the number of CD31 cells/
HPF was also significantly higher in nondiabetic wounds
compared with diabetic wounds (P  .05). eVasculogenesis. The effect of the lenti-SDF-1 inhib-
tor on vasculogenesis was assessed using immunohisto-
hemistry for -SMA. Representative images of immuno-
eroxidase staining for -SMA at 7 days in diabetic wounds
reated with lenti-GFP or lenti-SDF-1 inhibitor are dem-
nstrated in Fig 3, A and B, respectively. Vessel density per
PF was then quantified. Treatment of diabetic wounds
ith the lenti-SDF-1 inhibitor resulted in a significant
ecrease in vessel density (15.1	 4.1 vessels/HPF [n
 5];

 .018; Fig 4, E) compared with wounds treated with
enti-GFP (19.1 	 4.5 vessels/HPF [n 
 5]).
Representative images of immunoperoxidase staining
or -SMA at 7 days in nondiabetic wounds treated with
enti-GFP or lenti-SDF-1 are demonstrated in Fig 3, C
nd D, respectively. There was no significant difference in
asculogenesis between nondiabetic wounds treated with
enti-GFP or lenti-SDF-1 (27.9 	 4.41 vs 25 	 8.52
essels/HPF [both n 
 5]; Fig 3, E). However, diabetic
ounds had a significant decrease in vessel numbers/HPF
ompared with nondiabetic wounds (P  .0094).
Inflammation. The effect of SDF-1 inhibition on
nflammation was assessed using immunohistochemistry
or CD45, the common leukocyte antigen. Representa-
ive images of immunoperoxidase staining for CD45 at 7
ays in diabetic wounds treated with lenti-GFP or lenti-
DF-1 inhibitor are demonstrated in Fig 5, A and B,
espectively. Diabetic wounds treated with the lenti-
DF-1 inhibitor demonstrated a significant increase in
D45 cells/HPF of 22 	 12.9 (n 
 5; P  .005; Fig
, E) compared with 18 	 8.0 in lenti-GFP–treated
iabetic wounds (n 
 5).
Representative images of immunoperoxidase for CD45
t 7 days in nondiabetic wounds treated with lenti-GFP or
enti-SDF-1 inhibitor are demonstrated in Fig 5,C andD.
here was no significant difference in inflammatory cell
nfiltration in the nondiabetic wounds treated with lenti-
FP or lenti-SDF-1 inhibitor; however, there were signif-
cantly fewer CD45 cells in the nondiabetic wounds than
n the diabetic wounds (P  .002; Fig 5, E).
Inflammatory cytokine gene expression. Real-time
CR was used to assess inflammatory cytokine gene expres-
ion in diabetic and nondiabetic wounds treated with lenti-
FP or lenti-SDF-1 inhibitor. Diabetic wounds treated
ith the lenti-SDF-1 inhibitor demonstrated increased
nterleukin (IL)-6 gene expression at day 3 after wounding
s lenti-GFP treated wounds (7.5 	 2.1-fold vs 0.53 	
.14-fold; P 
 .016; Fig 6, A). By 7 days, there was no
ifference in IL-6 gene expression between groups. Dia-
etic wounds treated with the lenti-SDF-1 inhibitor also
emonstrated increased gene expression of macrophage
nflammatory protein-2 (MIP-2) at day 7 (1.98 	 0.49-
old vs 1.36 	 0.17-fold in lenti-GFP control; P 
 .026;
ig 6, A).
At 3 days, nondiabetic wounds treated with lenti-GFP
emonstrated decreased IL-6 expression (1 	 0.36-fold)
ompared with diabetic wounds treated with lenti-GFP
3.52 	 1.2-fold; P 
 .017). No difference in IL-6 gene
xpression was seen between groups treated with lenti-GFP
i
I
s
n).
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March 2011778 Bermudez et alat day 7. Nondiabetic wounds treated with lenti-GFP dem-
onstrated decreased MIP-2 gene expression at day 3 (4.36	
0.98-fold v 1 	 0.20-fold at day 3; P 
 .004) and post-
wounding day 7 (0.73	 0.17-fold vs 0.08	 0.009-fold at
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Fig 2. Representative sections of wound tissue are sho
black bar 
 200 m): in diabetic wounds treated wi
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lenti-SDFi.E,The graph showsmean volume of granulat
and SDFi (error bars show the standard error of the meaday 7; P 
 .002). bNondiabetic wounds treated with the lenti-SDF-1
nhibitor did not demonstrate any significant difference in
L-6 gene expression at 3 or 7 days. There was, however,
ignificant increase in MIP-2 gene expression in nondia-
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Volume 53, Number 3 Bermudez et al 779days (1.37 	 0.20-fold) vs nondiabetic wounds treated
with lenti-GFP (0.08 	 0.009-fold; P 
 .003). Fig 6, B
displays the relative-fold expression for IL-6 and MIP-2,
respectively, in both lenti-SDF-1 inhibitor and lenti-GFP-
treated nondiabetic wounds.
Cellular migration. Fibroblasts transduced with lenti-
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Fig 3. CD31 cells are shown at day 7 in a diabetic mice
lenti-stromal cell-derived factor-1 inhibitor (SDFi), an
lenti-SDFi (the black bars represent 25 m). E, The grap
groups (the error bars show the standard error of the meSDF-1 resulted in a significant increase in themigration of lplenic leukocytes (253 	 45 cells) compared with non-
ransduced fibroblasts (160	 39 cells; P
 .004; Fig 7) or
o cells (144 	 40 cells; P 
 .017). The addition of
broblasts transduced with the lenti-SDF-1 inhibitor,
ithout changing the number of total fibroblasts, resulted
n a dose-dependent decrease in the migration of splenic
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Wedemonstrate that SDF-1 is a key component in the
wound healing process and that competitive inhibition of
the activation of the CXCR4 receptor can alter the rate of
wound healing—especially in the diabetic mouse. Compet-
itive inhibition of SDF-1 significantly impairs the rate of
wound healing, decreases angiogenesis, and increases in-
flammation in the diabetic mouse. These are all features of
a chronic wound phenotype. In nondiabetic mice, the
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Fig 4. -Smooth muscle actin staining at 7 days after wo
fluorescent protein (GFP) or (B) lenti-stromal cell-derive
treated with (C) lenti-GFP or with (D) lenti-SDFi (black
at day 7 (error bars show the standard error of the meaninhibitor also decreases rate of wound healing early on and ts associated with increased inflammation. These findings
uggest a delay in wound healing, with the increased dura-
ion of an open wound, which may result in increased
nflammatory response to the persistent wound. Nondia-
etic wounds may be able to overcome this increased
nflammatory response, but diabetic wounds, which already
ave a disordered inflammatory response, may be unable to
ompensate for the increased inflammation.
Diabetic wounds are deficient in SDF-1,11 and correc-
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ng is shown in diabetic mice treated with (A) lenti-green
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Volume 53, Number 3 Bermudez et al 781noSDF-1deficiency innondiabeticmice, the levelofSDF-1
production required to overcome the effects of the inhibitory
vector are lower. These findings suggest a role for SDF-1 in
normal wound healing, but SDF-1 may have an even more
critical role in the pathogenesis of diabetic wound healing.
SDF-1 is a chemotactic factor regulating the migra-
tion of EPCs as well as leukocytes.25,26 EPC migration is
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March 2011782 Bermudez et altions of further wound healing impairment with SDF-1
inhibition, further support a role for SDF-1 in wound
healing and the diabetic impairment in healing.
SDF-1 is partly regulated through the transcriptional
activator hypoxia inducible factor-1.25 After injury, wound-
induced tissue hypoxia leads to upregulation of hypoxia in-
ducible factor-1.30 Toksoy et al31 has demonstrated that
there is a clear increase in the expression of SDF-1 at the
IL-6 levels 3 and 7 days after wounding
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Volume 53, Number 3 Bermudez et al 783These findings suggest that a lack of CXCR4 activation
results in impaired wound healing through decreased re-
cruitment of EPCs and subsequent angiogenesis. Overex-
pression of SDF-1 hastens wound healing in the diabetic
mouse and augments angiogenesis.20 Furthermore, mesen-
chymal stem cells have also been shown to correct the
deficiency of SDF-1 and promote granulation tissue for-
mation and improved wound healing.34
Diabetic wounds are known to be more abundant in
proinflammatory cytokines, and chronic inflammation has
been implicated in the pathogenesis of the diabetic wound-
healing impairment.14,19,35 We hypothesized that with in-
hibition of the CXCR4 receptor, the delay in wound heal-
ing may be due to chronic inflammation, supported by our
finding that there was greater CD45 infiltrate not only in
diabetic mice treated with control vector compared with
heterozygote mice treated with a control vector but also in
diabetic mice treated with the inhibitor. Impaired wound
healing may in fact increase the proinflammatory cytokines
circulating in the wound and ultimately result in a chronic
inflammatory state. Although no clear relationship exists at
the moment between inhibition of the CXCR4 pathway
and upregulation of inflammatory cytokines, these proin-
flammatory cytokines have a possible role in the develop-
ment and persistence of chronic wounds.35
We demonstrated increased inflammatory cells in dia-
betic wounds treated with the SDF-1 inhibitor at 7 days
compared with those treated with GFP. This increased
inflammation correlates with increased expression of IL-6
at 3 days andMIP-2 at 7 days. The impaired wound healing
in nondiabetic wounds treated with the SDF-1 inhibitor
was early in the course of wound healing and was corrected
by day 6. The correlation of this gene expression data and
wound closure is complicated because of the lag between
gene expression and the end result of the gene product.
Previous studies have demonstrated that expression of
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Fig 8. A, Schematic of the mechanism by which the stro
intracellular transduction at the CXCR4 receptor. Altho
binding, it does not activate a series of important intrace
wounds may be easier due to intrinsically low levels. This
wound. EPC, Endothelial progenitor cells;HIF-1, hypoxSDF-1 will promote cellular and leukocyte migration.32 the observation of a decline in leukocyte migration with
reater expressed levels of mutant SDF-1 confirms this
echanism of impaired cellular migration. That our animal
odel is a leptin-resistant diabetic mouse may confound
he picture. Leptin is known to promote angiogenesis, so
he differences illustrated in our study at baseline may be
xaggerated in a background of no leptin activity.
Novel approaches to treat diabetic wound healing are
acking. The application of growth factors, as in the case of
ecombinant PDGF, has been used to improve human
issue healing, but the results have not been dramatic.
iosynthetic grafts and hyperbaric oxygen therapy have
een used as a novel therapy to improve the diabetic
ound-healing process. These, too, have been met with
arginal success and, at times, prohibitive costs.36
ONCLUSIONS
SDF-1 is a highly conserved chemokine that plays a
ritical and multifaceted role in the wound-healing process
n normal and diabetic environments. We hypothesized
hat further decreases in SDF-1 functional activity would
esult in further impairments in diabetic healing and might
ffect nondiabetic healing. In addition, the diabetic
ound-healing impairment has been associated with
hronic inflammation. Chronic leg ulcers were significantly
ore infiltrated with inflammatory cells than one would
xpect in a well-healing wound.37
We hypothesized that delayed healing would result in
ncreased production of proinflammatory cytokines and
ncreased inflammation as seen in diabetic wounds. Fig 8
isplays what we suspect is the mechanism by which our
nhibitor has an effect on wound healing. Specifically, we
elieve that the impaired angiogenesis that occurs as a result of
he inhibitor sets into play a wound that heals poorly and is
tymied by chronic inflammation. Our results here appear to
upport these findings, with a marked increase in inflamma-
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JOURNAL OF VASCULAR SURGERY
March 2011784 Bermudez et alof SDF-1 activity. Although clearly more studies are needed
to define this relationship, SDF-1 may prove to be a key
factor in the wound-healing process that could be targeted to
correct the diabetic wound-healing defect.
We thank Dr Philip W. Zoltick of the Center for Fetal
Research at the Children’s Hospital of Philadelphia for
constructing the lentiviral vectors used in this project.
AUTHOR CONTRIBUTIONS
Conception and design: DB, KL
Analysis and interpretation: DB, JX
Data collection: DB, BH, JX, AR
Writing the article: DB, AR
Critical revision of the article: MM, KL
Final approval of the article: DB, KL
Statistical analysis: DB
Obtained funding: KL
Overall responsibility: KL
REFERENCES
1. United States Department of Health and Human Services. National
diabetes fact sheet. Washington, DC: The U.S. Department of Health
and Human Services; 2007.
2. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA,
et al. Causal pathways for incident lower-extremity ulcers in patients
with diabetes from two settings. Diabetes Care 1999;22:157-62.
3. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyberbaric oxy-
gen therapy for chronic wounds. Cochrane Database Syst Rev 2004:
CD004123.
4. Fife CE, Buyukcakir C, Otto G, Sheffield P, Love T, Warriner R 3rd.
Factors influencing the outcome of lower-extremity diabetic ulcers treated
with hyperbaric oxygen therapy. Wound Repair Regen 2007;15:322-31.
5. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors
in the treatment of diabetic foot ulcers. Br J Surg 2003;90:133-46.
6. Pierce GF, Tarpley JE, Tseng J, Bready J, Chang D, Kenney WC, et al.
Detection of platelet-derived growth factor (PDGF)-AA in actively healing
humanwounds treatedwith recombinant PDGF-BBand absence of PDGF
in chronic nonhealing wounds. J Clin Invest 1995;96:1336-50.
7. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel
formulation of recombinant human platelet-derived growth factor-BB
(becaplermin) in patients with chronic neuropathic diabetic ulcers: a
phase III randomized placebo-controlled double-blind study. Diabetes
Care 1998;21:822-7.
8. Keswani SG, Katz AB, Lim FY, Zoltick P, Radu A, Alaee D, et al. Adeno-
viral mediated gene transfer of PDGF-B enhances wound healing in type I
and type II diabetic wounds. Wound Repair Regen 2004;12:497-504.
9. Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological
dressings. Tiss Eng 2006;12:2407-24.
10. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of
Dermagraft in improving the healing of chronic diabetic foot ulcers: results
of a prospective randomized trial. Diabetes Care 2003;26:1701-5.
11. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, et al.
Diabetic impairments in NO-mediated endothelial progenitor cell mo-
bilization and homing are reversed by hyperoxia and SDF-1 alpha.
J Clin Invest 2007;117:1249-59.
12. Chow I, Lemos EV, Einarson TR. Management and prevention of
diabetic foot ulcers and infections: a health economic review. Pharma-
coeconomics 2008;26:1019-35.
13. Falanga V. Wound healing and its impairment in the diabetic foot.
Lancet 2005;366:1736-43.
14. Blakytny R, Jude E. The molecular biology of chronic wounds and
delayed healing in diabetes. Diabet Med 2006;23:594-608.15. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes
mellitus. Med Res Rev 2003;23:117-45. S6. Black E, Vibe-Peterson J, Jorgensen LN,Madsen SM,AgrenMS,Holstein
PE, et al. Decrease of collagen deposition inwound repair in type 1diabetes
independent of glycemic control. Arch Surg 2003;138:34-40.
7. Jude EB, Blakytny R, Bulmer J, Boulton AJ, FergusonMW. Transform-
ing growth factor-1. 2, 3 and receptor type I and II in diabetic foot
ulcers. Diabet Med 2002;19:440-7.
8. Fahey TJ, Sadaty A, Jones WG, Barber A, Smoller B, Shires GT.
Diabetes impairs the late inflammatory response to wound healing.
J Surg Res 1991;50:308-13.
9. FergusonMW, Herrick SE, Spencer MJ, Shaw JF, Boulton AJ, Sloan P.
The histology of diabetic foot ulcers. Diabet Med 1996;13:S30-33.
0. BadilloAT,ChungS,ZhangL,ZoltickP,LiechtyKW.Lentiviral gene transfer
of SDF-1 towounds improvesdiabeticwoundhealing. J SurgRes2007;143:
35-42.
1. Choi WT, Tian S, Dong CZ, Kumar S, Liu D, Madani N, et al. Unique
ligand binding sites on CXCR4 probed by a chemical biology approach:
implications for the design of selective human immunodeficiency virus
type 1 inhibitors. J Virol 2005;79:15398-404.
2. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a
tripartite posttranscriptional regulatory element. J Virol 1998;72:5085-92.
3. Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, et al. The
HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in
the brain. Nat Biotechnol 2001;19:446-50.
4. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW.
Optimized large-scale production of high titer lentivirus vector pseu-
dotypes. J Virol Methods 2004;122:131-9.
5. Ceradini DJ, Kulkarni AR, CallaghanMJ, Tepper OM, Bastidas N, Klein-
manME, et al. Progenitor cell trafficking is regulated by hypoxic gradients
through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
6. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization
and role in vascular biology. Circ Res 2004;95:343-53.
7. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz
GR, et al. Human endothelial progenitor cells from type II diabetics
exhibit impaired proliferation, adhesion, and incorporation into vascu-
lar structures. Circulation 2002;106:2781-6.
8. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, et al.
Number and function of endothelial progenitor cells as a marker of severity
for diabetic vasculopathy. Arterioscler ThrombVasc Biol 2006;26:2140-6.
9. Tepper OM, Carr J, Allen RJ Jr, Chang CC, Lin CD, Tanaka R, et al.
Decreased circulating progenitor cell number and failed mechanisms of
stromal cell-derived factor-1alpha mediated bone marrow mobilization
impair diabetic tissue repair. Diabetes 2010;59:1974-83.
0. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor
1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2
tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
1. Toksoy A, Müller V, Gillitzer R, Goebeler M. Biphasic expression of
stromal cell-derived factor-1 during human wound healing. Br J Der-
matol 2007;157:1148-54.
2. Badillo AT, Zhang L, Liechty KW. Stromal progenitor cells promote
leukocyte migration through production of stromal-derived growth factor
1alpha: a potential mechanism for stromal progenitor cell-mediated enhance-
ment of cellular recruitment to wounds. J Pediatr Surg 2008;43:1128-33.
3. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa
S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded
endothelial progenitor cells recruitment for ischemic neovasculariza-
tion. Circulation 2003;107:1322-8.
4. Badillo AT, Redden RA, Zhang L, Doolin EJ, Liechty KW. Treatment
of diabetic wounds with fetal murine mesenchymal stromal cells en-
hances wound closure. Cell Tiss Res 2007;329:301-11.
5. Singer AJ, Clark RAF. Cutaneous wound healing. N Engl J Med
1999;341:738-46.
6. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost
effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmaco-
economics 2003;21:1171-83.
7. Chen WY, Rogers AA. Recent insights into the causes of chronic leg
ulceration in venous diseases and implications on other types of chronic
wounds. Wound Repair Regen 2007;15:434-49.ubmitted Jun 15, 2010; accepted Oct 5, 2010.
